Coordinated activity among islet cells is necessary for glucose homeostasis. Chronic exposure to diabetogenic factors such as pro-inflammatory cytokines, perturbs islet cell crosstalk and β-cell function in diabetes. Secretory nanovesicles - exosomes (EXO) derived from cytokine exposed β-cells modulate physiological and pathological responses to β-cell stress. However, the mechanisms governing this process remain unknown. We tested the hypothesis that β-cell failure in diabetes is mediated in part through β-cell autocrine release of pro-inflammatory EXO to promote inflammation and inhibit β-cell function. Assessment of EXO concentrations from Min6 β-cells exposed to diabetogenic cytokines (IL-1β, TNF-α, and IFNγ, cytoEXO) revealed a 2-fold increase in EXO secretion (p<.05, vs. control (ctl) EXO). While acute inhibition of EXO formation with the compound GW4869 (neutral sphingomyelinase inhibitor) showed significant restoration in β-cell function (GSIS) in cytokine-exposed mouse and human islets (∼7 and 2 fold vs. cytokines alone, p<.05). Moreover, functional assessment of mouse islets exposed to cytoEXO (48h) resulted in suppression of GSIS (∼55%, vs. untreated, p<.05). Identification of cytoEXO content through proteomic analysis revealed a significant upregulation of the chemokine, CXCL10 (∼40 fold vs. ctlEXO) and RNA-Seq analysis of cytoEXO treated mouse islets depicted a marked upregulation of transcripts associated with CXCL10-CXCR3 signaling (p<.001) and subsequent downstream pathways (e.g., NFκB; p=.016 and JAK/STAT; p=.021). Furthermore, inhibition of cytoEXO (GW4869) with cytokines markedly decreased CXCL10 (∼30%) and CXCR3 (∼65%) expression in Min6 cells. These data suggests that cytokines enhance CXCL10 expression in β-cell EXO to enhance inflammation-induced diabetes through EXO-autocrine release of CXCL10 consequently activating CXCR3 signaling and downstream pathways to impair β-cell function.


N. Javeed: None. T.K. Her: None. M. Brown: None. P.M. Vanderboom: None. A.M. Egan: None. A. Vella: Advisory Panel; Self; vTv Therapeutics, Zealand Pharma A/S. Research Support; Self; Novo Nordisk A/S, Xeris Pharmaceuticals, Inc. I.R. Lanza: None. T. Patel: None. A. Matveyenko: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at